Mode
Text Size
Log in / Sign up

Systematic review and meta-analysis of herpes zoster risk in rheumatoid arthritis patientsRheumatoid Arthritis Patients Face Higher Shingles Risk Than General Public

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that several medications and comorbidities are significantly associated with increased herpes zoster risk in rheumatoid arthritis patients.

This is a systematic review and meta-analysis that synthesized data from 472,150 patients with rheumatoid arthritis to estimate the prevalence and risk factors for herpes zoster. The primary finding was a pooled proportion of herpes zoster of 6% (95% CI: 4%-8%), with a 95% prediction interval of 5% to 45% reflecting substantial heterogeneity.

The authors identified several factors significantly associated with increased herpes zoster risk. These included female gender (OR = 1.47; 95% CI: 1.15-1.89; P = 0.002), older age (OR = 1.12; 95% CI: 1.02-1.22; P = 0.012), and specific medication uses: corticosteroid dosage ≥7.5 mg/day (OR = 2.16; 95% CI: 1.85-2.53; P < 0.001), corticosteroid use (OR = 1.42; 95% CI: 1.19-1.69; P < 0.001), tumor necrosis factor inhibitors (OR = 1.94; 95% CI: 1.43-2.63; P < 0.001), methotrexate (OR = 1.68; 95% CI: 1.39-2.02; P < 0.001), and hydroxychloroquine (OR = 2.67; 95% CI: 1.24-5.74; P = 0.012).

Comorbidities also showed significant associations: pulmonary disease (OR = 1.42; 95% CI: 1.10-1.83; P = 0.007), hypertension (OR = 1.43; 95% CI: 1.15-1.77; P = 0.001), kidney disease (OR = 1.30; 95% CI: 1.04-1.62; P = 0.022), and heart disease (OR = 2.30; 95% CI: 1.17-4.52; P = 0.016).

The authors acknowledge limitations, including substantial heterogeneity as reflected by the wide prediction interval. They highlight the necessity for timely prevention and targeted strategies but do not report safety data, follow-up duration, or causality notes. Practice relevance is restrained, emphasizing the need for further research.

Imagine living with a chronic condition like rheumatoid arthritis. You manage your daily pain and stiffness with a strict routine. But there is another threat hiding in the shadows. This virus can strike without warning. It turns into painful shingles.

Shingles is a serious infection caused by the chickenpox virus. It stays dormant in your body for years. Then it wakes up and attacks your nerves. This causes a painful rash on one side of your body.

The Hidden Danger For RA Patients

Rheumatoid arthritis weakens your immune system. This makes you more vulnerable to infections. A new study looked at thousands of patients to find the truth. They found that 6% of people with rheumatoid arthritis get shingles. This number is much higher than the general public.

The study looked at data from many different countries. It included over 472,000 patients. The results show a clear pattern. People with rheumatoid arthritis are at greater risk. This is a significant burden on their health.

Why The Risk Is So High

Doctors have known that some medicines lower your immune defense. But this study found many other factors at play. Age is a big one. As you get older, your body fights viruses less well. Being female also increases the risk of getting this painful illness.

Medication plays a huge role in your safety. High doses of corticosteroids can double your risk. Some drugs used to treat rheumatoid arthritis also raise the danger. These include tumor necrosis factor inhibitors and methotrexate. Even hydroxychloroquine carries some added risk.

Understanding The Biology

Think of your immune system like a security guard. It patrols your body to stop invaders. When you take strong anti-inflammatory drugs, the guard takes a break. This leaves the door wide open for viruses.

The virus that causes shingles lies asleep in your nerves. It waits for the guard to get tired. Once the guard is on break, the virus wakes up. It travels along the nerve to your skin. This creates the burning pain and the rash.

Researchers combined data from seventeen different studies. They used strict rules to ensure the data was accurate. They looked at gender, age, and every major drug used. They also checked for other health problems like heart disease.

The findings were clear and consistent across all groups. High-dose steroids were the biggest risk factor. Using these drugs at 7.5 mg or more per day was very dangerous. Other conditions like kidney disease or heart disease also added to the risk.

This doesn't mean this treatment is available yet.

These results are important for your daily life. You should talk to your doctor about your medication list. Ask if you can lower your steroid dose safely. Discuss the risks of every drug you take.

Prevention is key to staying healthy. Your doctor might suggest the shingles vaccine. This shot can stop the virus from waking up. It is especially important for older adults and women.

No study is perfect. This research combined data from many places. This created some differences in how results were reported. The wide range of numbers shows that risk varies by person. Not every patient will get shingles. But the average risk is higher than you might think.

Doctors need to find better ways to protect patients. They must balance pain relief with infection safety. Future trials will look at new drugs. These new options might lower the risk of shingles. Until then, careful monitoring is essential.

Patients should stay informed about their health. Know your risk factors before starting new meds. Regular check-ups help catch problems early. Your doctor can adjust your plan to keep you safe.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
The co-occurrence of herpes zoster (HZ) in patients with rheumatoid arthritis (RA) represents a significant public health concern, with notable implications for both physical and mental health. This meta-analysis aims to systematically evaluate the pooled proportion of HZ in RA patients and identify associated factors. A comprehensive literature search was conducted across eight databases: PubMed, Web of Science, Embase, Cochrane Library, CNKI, VIP, WANFANG Data, and CBM. The review was conducted in accordance with PRISMA guidelines, and the quality of included studies was assessed using the Newcastle-Ottawa Scale (NOS). All statistical analyses were performed using Stata 17.0. A total of 17 observational studies (seven case-control and ten cohort) comprising 472,150 patients were included in this meta-analysis, indicating a descriptive pooled proportion of herpes zoster of 6% (95% CI: 4%-8%). However, the 95% prediction interval was 5% to 45%, reflecting substantial heterogeneity. This estimate represents an average across diverse settings rather than a universally generalizable figure. Eleven potential factors were evaluated, and the results indicated that the following were significantly associated with HZ in RA patients: female gender (OR = 1.47, 95% CI, 1.15-1.89, P = 0.002), age (OR = 1.12, 95% CI, 1.02-1.22, P = 0.012), corticosteroid dosage ≥7.5 mg/day (OR = 2.16, 95% CI, 1.85-2.53, P < 0.001), corticosteroid use (OR = 1.42, 95% CI, 1.19-1.69, P < 0.001), use of tumor necrosis associated factor inhibitors (OR = 1.94, 95% CI, 1.43-2.63, P < 0.001), methotrexate use (OR = 1.68, 95% CI, 1.39-2.02, P < 0.001), hydroxychloroquine use (OR = 2.67, 95% CI, 1.24-5.74, P = 0.012), history of pulmonary disease (OR = 1.42, 95% CI, 1.10-1.83, P = 0.007), history of hypertension (OR = 1.43, 95% CI, 1.15-1.77, P = 0.001), history of kidney disease (OR = 1.30, 95% CI, 1.04-1.62, P = 0.022), and history of heart disease (OR = 2.30, 95% CI, 1.17-4.52, P = 0.016). Our meta-analysis indicates that the observed 6% pooled proportion of HZ in patients with RA constitutes a significant burden compared to the general population, highlighting the necessity for timely prevention. Moreover, when assessing HZ risk, factors such as female gender, age, corticosteroid use and dosage ≥7.5 mg/day, use of tumor necrosis factor inhibitors, methotrexate, hydroxychloroquine, and a history of pulmonary disease, hypertension, kidney disease, or heart disease should be carefully considered. These findings highlight the need for further research into the associated factors and underlying biological mechanisms of HZ in RA patients and support the development of targeted prevention strategies that address modifiable risks. https://www.crd.york.ac.uk/PROSPERO/view/, identifier CRD420251050627.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.